Potential risk of alpha-glucosidase inhibitor administration in prostate cancer external radiotherapy by exceptional rectal gas production: a case report (original) (raw)

Abstract

Introduction: Radiotherapy is a standard treatment for prostate cancer, and image-guided radiotherapy is increasingly being used to aid precision of dose delivery to targeted tissues. However, precision during radiotherapy cannot be maintained when unexpected intrafraction organ motion occurs. Case presentation: We report our experience of internal organ motion caused by persistent gas production in a patient taking an alpha-glucosidase inhibitor. A 68-year-old Japanese man with prostate cancer visited our institution for treatment with helical tomotherapy. He suffered from diabetes mellitus and took an alpha-glucosidase inhibitor. Routine treatment planning computed tomography showed a large volume of rectal gas; an enema was given to void the rectum. Subsequent treatment planning computed tomography again showed a large volume of gas. After exercise (walking) to remove the intestinal gas, a third scan was performed as a test scan without tight fixation, which showed a sufficiently empty rectum for planning. However, after only a few minutes, treatment planning computed tomography again showed extreme accumulation of gas. Therefore, we postponed treatment planning computed tomography and consulted his doctor to suspend the alpha-glucosidase inhibitor, which was the expected cause of his persistent gas. Four days after the alpha-glucosidase inhibitor regimen was suspended, we took a fourth treatment planning computed tomography and made a treatment plan without gas accumulation. Thereafter, the absence of rectal gas accumulation was confirmed using daily megavolt computed tomography before treatment, and the patient received 37 fractions of intensity-modified radiotherapy at 74Gy without rectal gas complications. In this case study, the alpha-glucosidase inhibitor induced the accumulation of intestinal gas, which may have caused unexpected organ motion, untoward reactions, and insufficient doses to clinical targets. Conclusions: We suggest that patients who are taking an alpha-glucosidase inhibitor for diabetes should discontinue use of that particular medicine prior to beginning radiotherapy.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (13)

  1. Langen KM, Jones DTL: Organ motion and its management. Int J Radiat Oncol Biol Phys 2001, 50:265-278.
  2. Mutanga TF, de Boer HC, van der Wielen GJ, Hoogeman MS, Incrocci L, Heijmen BJ: Margin evaluation in the presence of deformation, rotation, and translation in prostate and entire seminal vesicle irradiation with daily marker-based setup corrections. Int J Radiat Oncol Biol Phys 2011, 81:1160-1167.
  3. Ogino I, Uemura H, Inoue T, Kubota Y, Nomura K, Okamoto N: Reduction of prostate motion by removal of gas in rectum during radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:456-466.
  4. Walton RJ, Sherif IT, Alberti KG: Improved metabolic profiles in insulin- treated diabetic patients given an alpha-glucosidehydrolase inhibitor. BMJ 1979, 6158:220-221.
  5. Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ, Reaven GM: Acarbose treatment of non-insulin-dependent diabetes mellitus. Arch Intern Med 1984, 144:345-347.
  6. Stasi M, Munoz F, Fiorino C, Pasquino M, Baiotto B, Marini P, Malinverni G, Valdagni R, Gabriele P: Emptying the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3D-CRT of prostate cancer. Radiother Oncol 2006, 80:363-370.
  7. Nijkamp J, Pos FJ, Nuver TT, de Jong R, Remeijer P, Sonke JJ, Lebesque JV: Adaptive radiotherapy for prostate cancer using kilovoltage con-beam computed tomography: first clinical results. Int J Radiat Oncol Biol Phys 2008, 70:75-82.
  8. Peeters ST, Lebesque JV, Heemsbergen WD, Hart AA, Koper PC, Lebesque JV: Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006, 64:1151-1161.
  9. Akimoto T, Muramatsu H, Takahashi M, Saito J, Kitamoto Y, Harashima K, Miyazawa Y, Yamada M, Ito K, Kurokawa K, Yamanaka H, Nakano T, Mitsuhashi N, Niibe H: Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 2004, 60:1033-1039.
  10. Herold DM, Hanlon AL, Hanks GE: Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 1999, 43:475-479.
  11. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrün S, Burman CM, Fuks Z, Leibel SA, Ling CC: Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000, 47:103-113.
  12. Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Valdagni R: Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3DCRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 2007, 67:1401-1410.
  13. Cheung R, Tucker SL, Ye JS, Dong L, Liu H, Huang E, Mohan R, Kuban D: Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1513-1519.